Breaking Research News from sources other than Breastcancer.org
Comments
-
This article explains how cancer treatment promotes cancer growth
Killing cancer softly: New approach halts tumor growth
Published Friday 1 December 2017
By Ana Sandoiu
Fact checked by Jasmin Collier
https://www.medicalnewstoday.com/articles/320227.p...
0 -
Compared with subjects sleeping immediately after supper, those sleeping two or more hours after supper had a 20% reduction in cancer risk for breast and prostate cancer. A similar protection was observed in subjects having supper before 9 pm compared with supper after 10 pm,
Effect of mistimed eating patterns on breast and prostate cancer risk (MCC‐Spain Study)
0 -
0
-
Check here to see if your doctor receives payments from drug companies.
0 -
Doctors Give Patients 11 Seconds to Explain Reason for Visit
https://www.studyfinds.org/doctors-give-patients-1...0 -
Here's the skinny:
The study, published by JAMA Internal Medicine, evaluated nearly 1.6 million elderly Medicare holders hospitalized from Jan. 1, 2011 to Dec. 31, 2014. It determined that patients treated by female doctors had significantly lower rates of death and significantly lower rates of readmission to the hospital than patients who were treated by male doctors at the same hospital.
0 -
I haven't been on in a while due to my very crazy schedule.
I saw the discussion about California labeling regarding substances "known to the State of California to cause cancer or reproductive toxicity." We've (almost) all seen these on nationally marketed products and the signs are ubiquitous in California. For many years, I have wondered, is California the only one demanding meaningful labeling or have they gone way overboard? The contrast of silence from all other quarters vs the abundance of labeling in California is jarring. It's hard to know where to start, but for those interested in reading more on the topic, here's a link to the American Cancer Society's briefing on the subject. https://www.cancer.org/cancer/cancer-causes/genera...
For those looking for additional perspectives, the organization Breast Cancer Action seems to be active in raising concerns related to environmental issues as possible causes of cancer. There is also a book on the topic, No Family History, by Sabrina McCormick. Not sure whether there is a forum on BC.org on the topic....?
0 -
Safety by Body Weight of Adjuvant Subcutaneous Trastuzumab for HER2+ Early Breast Cancer
https://www.practiceupdate.com/C/71137/56?elsca1=e...
- This is a report of subgroup analyses of the SafeHer trial, evaluating the safety by body weight of fixed-dose subcutaneous trastuzumab as adjuvant treatment for early-stage, HER2-positive breast cancer.
- The safety profile was consistent across subgroups of body weight and the overall patient population, including those with lowest body weight and those of Asian origin.
I was thrilled to see that further study is being done on Subcutaneous Trastuzumab for HER2+ Breast Cancer. Alas, none of the study centers is in the U.S. (We need access to this mode of therapy in the states!) The link to clinical trial info is:
0 -
Toxins and the Immune system
300,000 new chemicals are listed each year! How can that be?
http://www.immunesystemetc.com/Toxins.html0 -
That is very disturbing Marijen. I can’t believe the amount of toxins that exists!!! Ugh!
0 -
Warrior it just impossible to avoid all the chemicals. I give up
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline: Journal of Clinical Oncology: Vol 35, No 18
http://ascopubs.org/doi/10.1200/JCO.2016.70.7257
0 -
Marijen, Thank you...I go for my 5th Zometa infusion next Friday (every 6 months).
0 -
I've just had my 5th Prolia injection - also every 6 months.
0 -
So 7of9 and Minus Two, you are getting these treatments as preventative? I had three yearly reclast, two before BC dx and 1 after. Don’t know why but my endocrinologist won’t give me more. I thought they made me feel better in the bones and muscles. Osteoporosis.
0 -
Estrogen regulates the brain's fear response, protecting against PTSD
https://www.medicalnewstoday.com/articles/315383.p...0 -
marijen - no I had osteoporosis from the treatments. I sent you a PM.
0 -
yes, mine are preventative though diagnosed with mild osteo
0 -
I know the value of estrogen re: regulating emotions, but I'm glad to have this article. At least I know my abject fear about everything at times, and my recurrent PTSD, isn't simply a character flaw.
0 -
I know the value of estrogen re: regulating emotions, but I'm glad to have this article about estrogen and PTSD. At least I know my abject fear about everything at times, and my recurrent PTSD, isn't simply a character flaw.
0 -
FDA Approves Magnetic Localization System for Lymph Node Biopsy in Breast Cancer
https://www.onclive.com/web-exclusives/fda-approve...0 -
Association of Circulating Tumor Cells With Late Recurrence of ER+ Breast Cancer
https://www.practiceupdate.com/C/71320/56?elsca1=e...
- In this secondary analysis of a randomized clinical trial, circulating tumor cells were detectable in 26 of 547 patients (4.8%) with localized breast cancer 5 or more years after diagnosis. Circulating tumor cells were also associated with a higher risk of recurrence among patients with hormone receptor–positive breast cancer.
- Circulating tumor cells may be used to stratify for risk of late recurrence among patients with hormone receptor–positive breast cancer.
0 -
Psychosocial Outcomes of Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer
https://www.practiceupdate.com/C/71318/56?elsca1=e...
- This study prospectively examined psychosocial outcomes before and up to 18 months after surgery in women with nonhereditary breast cancer who did and did not have contralateral prophylactic mastectomy (CPM). A total of 288 women provided questionnaire data, of whom 50 underwent CPM. Before surgery, women who subsequently received CPM had higher cancer distress, cancer worry, and body image concerns than women who did not have CPM. Quality of life was similar between the two groups before surgery but declined 1 month after surgery and remained lower in women who underwent CPM.
- These results may facilitate informed discussions between women and their physicians regarding CPM. Fear and worry may be foremost concerns at the time surgical decisions are made, when women may not anticipate the adverse future effect of CPM on body image and quality of life.
0 -
Impact of the Second Reader on Screening Outcomes at Blinded Double Reading of Digital Screening Mammograms
https://www.practiceupdate.com/C/71423/56?elsca1=e...
- This prospective study compared outcomes of blinded double vs single readings of screening mammograms on detection rates of breast cancer.
- The second reader program increased the cancer detection rate, but also increased the recall rate and false-positive rate.
0 -
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
https://www.ncbi.nlm.nih.gov/pubmed/27669438
Abstract
The CXCR4 receptor and its ligand CXCL12 (also named stromal cell-derived factor 1, SDF1) have a critical role in chemotaxis and homing, key steps in cancer metastasis. Although myofibroblasts expressing CXCL12 are associated with the presence of axillary metastases in HER2 breast cancers (BC), the therapeutic interest of targeting CXCR4/CXCL12 axis in the different BC subtypes remains unclear. Here, we investigate this question by testing antitumor activity of CXCR4 inhibitors in patient-derived xenografts (PDX), which faithfully reproduce human tumor properties. We observed that two CXCR4 inhibitors, AMD3100 and TN14003, efficiently impair tumor growth and metastasis dissemination in both Herceptin-sensitive and Herceptin-resistant HER2 BC. Conversely, blocking CXCR4/CXCL12 pathway in triple-negative (TN) BC does not reduce tumor growth, and can even increase metastatic spread. Moreover, although CXCR4 inhibitors significantly reduce myofibroblast content in all BC subtypes, they decrease angiogenesis only in HER2 BC. Thus, our findings suggest that targeting CXCR4 could provide some therapeutic interest for HER2 BC patients, whereas it has no impact or could even be detrimental for TN BC patients.
PMID: 27669438 PMCID: PMC5340801 DOI: 10.1038/onc.2016.284
0 -
CXCR4 Antagonists and Breast Cancer
https://www.practiceupdate.com/c/69235/67/13/?elsc...
{video/interview} Timothy J Pluard MD
"...we saw a significant response rate of about 36% in these heavily pretreated patients and about 60+% clinical benefit in these patients. So, there's a signal there that's obviously a phase I trial with early data, but I think it gives us the groundwork to move forward with additional studies. The FDA has granted fast track designation, so we're moving forward with additional studies."
{poster note: This sounds very promising!}
0 -
Increased Out-of-Pocket Expenditures Among Women With Metastatic Breast Cancer in High-Deductible Health Plans
https://www.practiceupdate.com/c/69776/67/13/?elsc...
- In this longitudinal study, data of 5364 women with metastatic breast cancer who were insured by a large US insurer from 2004 to 2011 were evaluated to determine trends in total and out-of-pocket costs. The percentage of women enrolled in high-deductible health plans increased from 8% to 23%, whereas the percentage enrolled in low-deductible health plans decreased from 69% to 37%. Overall, the estimated annual inflation-adjusted health service spending increased $1197 per year; annual out-of-pocket spending did not change. Women in high-deductible health plans reported 55% more out-of-pocket spending compared with women in low-deductible health plans.
- These findings highlight the need for new health plans that protect patients with metastatic breast cancer from high out-of-pocket costs.
Published in Metastatic Breast Cancer July 25, 2018
0 -
Surgeon Attitudes Toward the Omission of Axillary Dissection in Early Breast Cancer
https://www.practiceupdate.com/C/70820/56?elsca1=e...
- In this survey of 376 surgeons, 49% would definitely or probably recommend axillary dissection for one sentinel node macrometastasis and 63% would definitely or probably recommend axillary dissection for two sentinel node macrometastases. In multivariable analysis, a lower propensity for axillary dissection was significantly associated with treatment of more breast cancer cases, acceptance of a lumpectomy margin of no ink on tumor, multidisciplinary tumor board participation, and Los Angeles SEER site.
- The potential for overtreatment identified in this study indicates the need for education targeted toward lower-volume breast surgeons.
0 -
Women with higher vitamin D blood levels have lower risk for breast cancer
https://www.news-medical.net/news/20180618/Women-w...
Results from a new study published in PLOS ONE shows women who have higher vitamin D blood levels have a significantly lower risk for breast cancer.
0 -
Clinical trial results of tucatinib with T-DM1 shows promise in treating HER2+ breast cancer
https://www.news-medical.net/news/20180711/Clinica...
Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib (formerly ONT-380) with T-DM1 against heavily pretreated HER2-positive breast cancer. Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months. Importantly, tucatinib acted against brain metastases stemming from HER2+ breast cancer, a major cause of mortality from the disease.
"One of the best things about this drug is that it combines well with nearly everything. It is so well tolerated that when you test tucatinib in combination with other drugs, it feels like you're just giving the other drug. It's a pill. It works. And it hardly causes side effects. It's really a doctor's dream," says Virginia Borges, MD, MMSc, director of the Breast Cancer Research Program and Young Women's Breast Cancer Translational Program at CU Cancer Center.
.... tucatinib is being evaluated in a number of other trials and with additional partners...
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer
https://www.practiceupdate.com/c/70229/67/13/?elsc...
- In this phase IB study of 57 patients with metastatic or unresectable locally advanced ERBB2/HER2-positive breast cancer treated previously with trastuzumab and a taxane, the maximum tolerated dosage of tucatinib combined with ado-trastuzumab emtansine was determined to be 300 mg administered orally twice daily; the objective response rate was 48%. Median progression-free survival was 8.2 months.
- Tucatinib in combination with ado-trastuzumab emtansine had acceptable toxicity and showed preliminary antitumor activity among heavily pretreated patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases.
0 -
Managing multiple ipsilateral breast cancer with potential new surgical options
https://www.news-medical.net/news/20180713/Managin...
A new multi-institutional clinical trial compared outcomes of women with multiple ipsilateral breast cancer, or more than one site of disease in the same breast, who underwent breast-conserving surgery, with outcomes of those who converted to mastectomy. Out of 198 eligible women in the trial, 184 (92.9%) successfully completed breast-conserving surgery, 134 of those with a single operation. These findings have just been published online first in Annals of Surgical Oncology.
0
